HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management
- 19 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 14 (5), 581-592
- https://doi.org/10.1158/1940-6207.capr-20-0465
Abstract
To assess the impact of HCV eradication on the outcomes of cirrhotic patients treated curatively for incidental hepatocellular carcinoma (HCC) detected during surveillance program. Data were collected on 1323 French patients with compensated biopsy-proven HCV cirrhosis recruited in 35 centers (ANRS CO12 CirVir cohort). Sustained virological responses (SVR) and the occurrence of HCC were recorded prospectively. During a median follow-up (FU) of 68.3 months, 218 patients developed HCC, 126 of whom underwent a curative procedure as first-line therapy (ablation=95, resection=31). The HCC BCLC stage was 0/A in 97.5% of patients; 74 (58.7%) never achieved SVR. During a median FU of 26.0 months after HCC treatment, 59 (46.8%) experienced HCC recurrence. SVR was not associated with a recurrence, whether considering final SVR status (HR=0.77 [0.43; 1.39]; P=0.39) or its time to achievement (prior to/after HCC occurrence; global P=0.28). During the same timeframe, 46 HCC patients (36.5%) died (liver failure: 41.9%, HCC progression: 37.2%, extrahepatic causes: 20.9%). Under multivariate analysis, SVR was associated with improved survival (HR=0.21 [0.08; 0.52]; P=0.001). Survival benefit was explained by a lower incidence of liver decompensation and higher rates of sequential HCC re-treatment. Direct antivirals intake was not associated with a higher risk of HCC recurrence but with improved survival (HR=0.23 [0.06; 0.83]; P=0.024). HCV eradication in primary or secondary prevention optimizes HCC management through preservation of liver function and improves survival, whatever the regimen.Keywords
Other Versions
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
This publication has 34 references indexed in Scilit:
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infectionJournal of Hepatology, 2014
- A systematic review and meta‐analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis‐related hepatocellular carcinomaJournal of Viral Hepatitis, 2013
- Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver CancerClinical Cancer Research, 2013
- Low Hepatitis C Viral Load Predicts Better Long-Term Outcomes in Patients Undergoing Resection of Hepatocellular Carcinoma Irrespective of Serologic Eradication of Hepatitis C VirusJournal of Clinical Oncology, 2013
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosisJournal of Hepatology, 2010
- Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approachJournal of Hepatology, 2010
- Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatology, 2006
- Management of hepatocellular carcinomaHepatology, 2005